Nano to Clinic: Bridging the Gap with Translational Cancer Bioimaging

Authors: Shukla V*

DOI: 10.23880/nnoa-16000337

Volume 9, Issue 4

Abstract

Nanoparticle-based imaging agents have opened new horizons in cancer diagnostics and treatment due to their unprecedented precision and versatility. Such agents enhance the resolution of imaging, improve biodistribution, and minimize systemic toxicity, which in turn will help clinicians for more accurate diagnosis, staging, and treatment monitoring. While significant preclinical successes have been achieved so far, clinical translation still faces several challenges such as regulatory issues, scalability, and patient safety. While large amounts of data on their safety, efficacy, and biocompatibility have been necessitated by the regulatory agencies, more complexities include nanoparticle variability and bioaccumulation. Recent scalable manufacturing, safe-by-design strategies, and AI improvement overcame these challenges. Integration of nanoparticles with immunotherapy, personalized nanomedicine—all are the new emerging trends in next-generation cancer treatment. Publicprivate collaborations, together with government support, have given further impetus in this direction. It probes the state of translational cancer bioimaging today by underlining how the gap in crossing from bench to clinic must be bridged in innovative ways through interdisciplinary involvement for this impact in cancer care to be profound

Keywords: Nanoparticle-Based Imaging Agents; Cancer Diagnostics; Translational Bioimaging; Clinical Trials and Personalized Nanomedicine

View PDF